Hyperfine (HYPR) Income from Continuing Operations (2021 - 2026)
Hyperfine (HYPR) posted Income from Continuing Operations of 8623000.0 for Q1 2026, down 45.86% on a QoQ basis from 5912000.0 in Q4 2025, and up 8.44% year-over-year from 7951768.73 in Q1 2025.
Hyperfine (HYPR) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Hyperfine's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 8623000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 8.44% year-over-year to 8623000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34779000.0 (up 13.68% YoY) and the FY2025 annual result came in at 35574000.0, up 12.64% from the prior year.
- Income from Continuing Operations was 8623000.0 for Q1 2026 at Hyperfine, down from 5912000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5912000.0 in Q4 2025 and bottomed at 23775000.0 in Q1 2022.
- A 5-year average of 11901117.65 and a median of 10637000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 205.04% — and 2023, when it surged 54.07%.
- Hyperfine's Income from Continuing Operations stood at 13059000.0 in 2022, then climbed by 18.19% to 10684000.0 in 2023, then advanced by 2.75% to 10390000.0 in 2024, then jumped by 43.1% to 5912000.0 in 2025, then plunged by 45.86% to 8623000.0 in 2026.
- Business Quant data shows HYPR's Income from Continuing Operations at 8623000.0 in Q1 2026, 5912000.0 in Q4 2025, and 11019000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | -8.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.62 Mn |
| Dec 31, 2025 | -5.91 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -9.23 Mn |
| Mar 31, 2025 | -9.42 Mn |
| Dec 31, 2024 | -10.39 Mn |
| Sep 30, 2024 | -10.33 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Mar 31, 2024 | -9.85 Mn |
| Dec 31, 2023 | -10.68 Mn |
| Sep 30, 2023 | -10.76 Mn |
| Jun 30, 2023 | -10.64 Mn |
| Mar 31, 2023 | -12.16 Mn |
| Dec 31, 2022 | -13.06 Mn |
| Sep 30, 2022 | -13.17 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -23.78 Mn |
| Dec 31, 2021 | -26.09 Mn |
| Sep 30, 2021 | -16.39 Mn |
| Jun 30, 2021 | -14.58 Mn |